Market Price

1.48 

0.03 2.2%

as of May 16 '22

52 Week Range:

1.43 2.60


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. The company's Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase I clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is headquartered in Bergen, Norway.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Oct '11 Oct '12 Oct '13 Oct '14 Oct '15 Oct '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 0.07
0.11
0.12
0.16
0.17
0.20
0.45
0.80
0.51
growth rate 57.1% 9.1% 33.3% 6.3% 17.7% 31.0% 77.8% -36.3%
Earnings BIT 63.00
16.00
33.00
-131.57
-183.71
-194.54
-204.38
-261.09
growth rate -74.6% 106.3% -100.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE 2.43
1.86
-0.56
-0.56
-0.56
growth rate -23.5% -100.0% 0.0% 0.0%
ROA 21.04
24.83
16.69
1.31
-87.52
-101.04
-65.21
-50.25
-61.39
-50.97
-52.06
growth rate 18.0% -32.8% -92.2% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE 28.65
40.16
32.86
2.57
-111.37
-119.07
-72.36
-55.77
-71.55
-57.76
-58.67
growth rate 40.2% -18.2% -92.2% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC 24.16
27.91
26.32
4.28
-111.34
-119.85
-73.46
-56.78
-72.17
-58.49
-59.05
growth rate 15.5% -5.7% -83.7% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 1.49
0.95
0.82
0.71
6.80
8.19
11.29
9.10
5.32
11.05
6.92
growth rate -36.2% -13.7% -13.4% 857.8% 20.4% 37.9% -19.4% -41.5% 107.7% -37.4%
Quick Ratio 1.43
0.87
0.69
0.70
6.09
7.59
10.90
8.66
5.00
10.83
6.73
growth rate -39.2% -20.7% 1.5% 770.0% 24.6% 43.6% -20.6% -42.3% 116.6% -37.9%
Leverage 1.36
1.79
2.09
1.86
1.27
1.14
1.09
1.12
1.23
1.10
1.17
growth rate 31.6% 16.8% -11.0% -31.7% -10.2% -4.4% 2.8% 9.8% -10.6% 6.4%
Balance Sheet Oct '11 Oct '12 Oct '13 Oct '14 Oct '15 Oct '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 74.00
64.00
224.00
12.08
12.99
17.34
15.45
13.50
growth rate -13.5% 250.0% -94.6% 7.5% 33.5% -10.9% -12.6%
Acct.Payable 97.00
81.00
136.00
10.70
21.58
23.94
26.75
22.55
growth rate -16.5% 67.9% -92.1% 101.6% 11.0% 11.7% -15.7%
Cur.Assets 157.00
121.00
253.00
174.13
383.78
378.25
269.40
735.87
growth rate -22.9% 109.1% -31.2% 120.4% -1.4% -28.8% 173.2%
Total Assets 384.00
376.00
570.00
174.54
384.34
378.83
270.38
738.20
growth rate -2.1% 51.6% -69.4% 120.2% -1.4% -28.6% 173.0%
Cash 24.00
15.00
18.00
161.83
370.35
360.41
253.59
721.64
growth rate -37.5% 20.0% 799.0% 128.9% -2.7% -29.6% 184.6%
Inventory 2.00
1.00
2.00
7.00
growth rate -50.0% 100.0% 250.0%
Cur.Liabilities 191.00
170.00
288.00
21.27
33.99
41.55
50.62
66.60
growth rate -11.0% 69.4% -92.6% 59.8% 22.2% 21.9% 31.6%
Liabilities 200.00
174.00
298.00
21.27
33.99
41.55
50.62
67.97
growth rate -13.0% 71.3% -92.9% 59.8% 22.2% 21.9% 34.3%
LT Debt 4.00
5.00
5.00
0.00
growth rate 25.0% 0.0% -81.8%
Equity 153.27
350.35
337.28
219.75
670.23
growth rate 128.6% -3.7% -34.9% 205.0%
Common Shares 830.00
890.00
888.00
888.00
51.00
51.00
46.00
54.00
58.00
75.00
88.00
growth rate 7.2% -0.2% 0.0% -94.3% 0.0% -9.8% 17.4% 7.4% 29.3% 17.3%
Cash Flow Statement Oct '11 Oct '12 Oct '13 Oct '14 Oct '15 Oct '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 75.00
45.00
14.00
0.26
0.34
0.23
0.07
0.07
growth rate -40.0% -68.9% -98.2% 33.3% -32.9% -70.6% 0.0%
Cash From OA 103.00
29.00
-59.00
-124.31
-168.11
-186.71
-186.68
-234.29
growth rate -71.8% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -0.01
-0.02
-0.03
-0.01
-0.06
-0.34
-0.28
-0.33
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF 5.00
-19.00
28.00
-16.00
-63.00
-125.00
-168.00
-187.00
-184.00
-234.00
-303.00
growth rate -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Oct '11 Oct '12 Oct '13 Oct '14 Oct '15 Oct '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 270.00
336.00
419.00
350.00
2.34
8.90
0.60
growth rate 24.4% 24.7% -16.5% -91.8% 281.2% -93.3%
Op.Income 63.00
16.00
33.00
-131.57
-183.71
-194.54
-204.38
-261.09
growth rate -74.6% 106.3% -100.0% 0.0% 0.0% 0.0% 0.0%
IBT -129.80
-182.21
-191.75
-199.28
-257.03
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income 50.00
5.00
34.00
-129.80
-182.21
-191.75
-199.28
-257.03
growth rate -90.0% 580.0% -100.0% 0.0% 0.0% 0.0% 0.0%
EPS 0.03
0.04
0.06
0.01
-236.34
-2.57
-3.94
-3.54
-3.43
-3.43
-3.52
growth rate 33.3% 50.0% -83.3% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 77.00
43.00
32.00
25.00
2.34
8.90
0.60
growth rate -44.2% -25.6% -21.9% -69.4% 281.2% -93.3%

Quarterly Statements

Item Name Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Earnings BIT -68.31
-71.82
-83.42
-92.31
-71.42
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Acct.Receivable 15.97
13.50
10.54
7.76
3.02
growth rate -15.5% -21.9% -26.4% -61.1%
Acct.Payable 23.44
22.55
32.70
15.93
22.28
growth rate -3.8% 45.0% -51.3% 39.9%
Cur.Assets 794.83
735.87
671.05
582.94
513.49
growth rate -7.4% -8.8% -13.1% -11.9%
Total Assets 795.21
738.20
673.21
584.78
514.99
growth rate -7.2% -8.8% -13.1% -11.9%
Cash 777.86
721.64
659.39
574.03
509.41
growth rate -7.2% -8.6% -12.9% -11.3%
Inventory
growth rate
Cur.Liabilities 52.87
66.60
72.63
68.64
63.86
growth rate 26.0% 9.0% -5.5% -7.0%
Liabilities 52.87
67.97
73.94
69.88
64.87
growth rate 28.6% 8.8% -5.5% -7.2%
LT Debt 0.00
1.31
1.24
1.02
growth rate 130,800.0% -5.3% -18.1%
Equity 742.35
670.23
599.28
514.89
450.12
growth rate -9.7% -10.6% -14.1% -12.6%
Common Shares 8.73
8.73
8.78
8.80
8.83
growth rate 0.0% 0.6% 0.2% 0.3%
Cash Flow Statement Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Capital Expenditures 0.07
0.07
growth rate 0.0%
Cash From OA -68.80
-53.02
-70.79
-84.43
-67.18
growth rate 0.0% 0.0% 0.0% 0.0%
FCF -68.87
-53.09
growth rate 0.0%
Income Statement Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Sales 0.60
growth rate
Op.Income -68.31
-71.82
-83.42
-92.31
-71.42
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -67.32
-73.87
-81.24
-88.86
-70.50
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -67.32
-73.87
-81.24
-88.86
-70.50
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit 0.60
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -0.56 -4.07
EPS / Growth -0.36

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 40.0% 50.0% 78.7%
Future PE 0.01 0.01 52.46
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.